As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Compass Therapeutics, Inc. The largest reported stake is Tang Capital Management, LLC's, at 9.99%. 18 filings are on record since July 16, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Compass Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 7,207,573 · Shared voting: 0 · Sole dispositive: 7,207,573 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 9,687,331 · Sole dispositive: 0 · Shared dispositive: 9,953,653 · SCHEDULE 13G, 2026-08-07
- · Holder: Bvf Partners L P · Percent: 4.3% · SCHEDULE 13G/A
- · Holder: Blackstone Alternative Asset Management Associates LLC · Percent: 3.4% · SCHEDULE 13G/A
- · Holder: BlackRock, Inc. · Percent: 5.2% · SCHEDULE 13G
Compass Therapeutics, Inc. has 18 Schedule 13D or 13G filings on record since 2025-07-16. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Tang Capital Management, LLC | 9.99% | 17,176,510 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Orbimed Advisors LLC | 8.9% | 15,219,994 | SCHEDULE 13D/A, 2025-08-15 | 2025-08-13 |
| Suvretta Capital Management, LLC | 8.2% | 14,101,159 | SCHEDULE 13G/A, 2025-08-21 | 2025-08-13 |
| State Street Corporation | 5.5% | 9,953,653 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| BlackRock, Inc. | 5.2% | 9,271,644 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
| Commander Aggregator, LP | 4.5% | 7,788,150 | SCHEDULE 13D/A, 2025-08-18 | 2025-08-14 |
| Bvf Partners L P | 4.3% | 7,764,842 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| MPM BioImpact LLC | 4.1% | 5,622,505 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| Vivo Opportunity Fund Holdings, L.P. | 4% | 7,207,573 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Blackstone Alternative Asset Management Associates LLC | 3.4% | 6,126,182 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| RTW Investments, LP | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Compass Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Compass Therapeutics, Inc. and the records around it.
Compass Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- MPM BioImpact LLC also filed stake reports on 4 other companies: Climb Bio, Inc. (Aug 2026), Context Therapeutics Inc. (Aug 2026), DBV TECHNOLOGIES S.A. (Aug 2026)
- Blackstone Annex Master Fund L.P. also filed stake reports on 7 other companies: Corebridge Financial, Inc. (Nov 2026), Jersey Mike's Subs Inc. (Nov 2026), VARAGON CAPITAL CORPORATION (Oct 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Pasithea Therapeutics Corp. (Aug 2026)
Watch Compass Therapeutics, Inc.
Get an email when Compass Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Compass Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Compass Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Compass Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| State Street Corporation | 0 | 9,687,331 | 0 | 9,953,653 | SCHEDULE 13G, 2026-08-07 |
| Vivo Opportunity Fund Holdings, L.P. | 7,207,573 | 0 | 7,207,573 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Vivo Opportunity, LLC | 7,207,573 | 0 | 7,207,573 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Vivo Opportunity Cayman Fund, L.P. | 549,487 | 0 | 549,487 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Vivo Opportunity Cayman, LLC | 549,487 | 0 | 549,487 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Compass Therapeutics, Inc. by CUSIP 20454B104 and gives its principal executive office as 80 Guest St., Suite 601, Boston, MA 02135 (SCHEDULE 13G/A, 2026-08-14).
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-08-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 4.6% | SCHEDULE 13G/A |
| 2025-08-12 | MPM BioImpact LLC | 4.1% | SCHEDULE 13G/A |
| 2025-08-13 | Suvretta Capital Management, LLC | 5.2% | SCHEDULE 13G |
| 2025-08-14 | Tang Capital Management, LLC | 9.8% | SCHEDULE 13G/A |
| 2025-08-14 | RTW Investments, LP | 9.9% | SCHEDULE 13G/A |
| 2025-08-14 | RTW Investments, LP | 0% | SCHEDULE 13G/A |
| 2025-08-15 | Orbimed Advisors LLC | 8.9% | SCHEDULE 13D/A |
| 2025-08-18 | Commander Aggregator, LP | 4.5% | SCHEDULE 13D/A |
| 2025-08-21 | Suvretta Capital Management, LLC | 8.2% | SCHEDULE 13G/A |
| 2025-10-29 | Bvf Partners L P | 5.1% | SCHEDULE 13G |
| 2025-11-14 | Vivo Opportunity Fund Holdings, L.P. | 5.1% | SCHEDULE 13G |
| 2025-11-14 | Tang Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Tang Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 5.2% | SCHEDULE 13G |
| 2026-02-13 | Blackstone Alternative Asset Management Associates LLC | 3.4% | SCHEDULE 13G/A |
| 2026-05-15 | Bvf Partners L P | 4.3% | SCHEDULE 13G/A |
| 2026-08-07 | State Street Corporation | 5.5% | SCHEDULE 13G |
| 2026-08-14 | Vivo Opportunity Fund Holdings, L.P. | 4% | SCHEDULE 13G/A |
Questions about who owns Compass Therapeutics, Inc.
Who owns Compass Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Compass Therapeutics, Inc.: Tang Capital Management, LLC (9.99%, Schedule 13G/A, filed 2025-11-14), Orbimed Advisors LLC (8.9%, Schedule 13D/A, filed 2025-08-15), Suvretta Capital Management, LLC (8.2%, Schedule 13G/A, filed 2025-08-21), State Street Corporation (5.5%, Schedule 13G, filed 2026-08-07) and BlackRock, Inc. (5.2%, Schedule 13G, filed 2026-01-21).
Who are the largest shareholders of Compass Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Compass Therapeutics, Inc. on this page are Tang Capital Management, LLC (9.99%), Orbimed Advisors LLC (8.9%) and Suvretta Capital Management, LLC (8.2%).
When did Tang Capital Management, LLC buy into Compass Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Tang Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.8%; its latest, Schedule 13G/A filed 2025-11-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Compass Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.